Like many of the young biotechnology companies it incubates, Forward BIOLABS is moving past its own early stage, celebrating the success it’s seen so far by initiating a series of developments that will expand its presence in Madison, launch a second site, and offer a new source of targeted funding for businesses to grow.
The moves come as two of Forward BIOLABS’s stars hit impressive milestones. Elephas, with a novel way to predict cancer treatment’s effectiveness, has notched more than $150 million in private investments, and Axio BioPharma, whose technology speeds drug development, is about to start raising its first major funding round.
“Forward BIOLABS speeds up research and turns ideas into real products faster, strengthening Wisconsin’s position as a leader in biohealth innovation,” says Shayna Hetzel, WEDC’s vice president of entrepreneurship and innovation.
“A state-of-the-art coworking lab, combined with a welcoming on-ramp into the community, draws top talent—founders, scientists, and engineers—who thrive in collaborative ecosystems with robust resources. It signals that Wisconsin is a destination of choice for innovators and entrepreneurs,” Hetzel says.
Read the full story here: https://wedc.org/forward-biolabs-charts-its-next-phase/